末期腎不全（ESRD）とは、腎臓の機能が完全に、あるいは殆ど喪失した状態のことを指します。主な症状として、排尿不全や倦怠感、頭痛、食欲不振、悪心嘔吐、骨の痛み、意識混濁、集中力低下などが挙げられます。主なリスク要因には、多発性嚢胞腎疾患やアルポート症候群、間質性腎炎、一部の自己免疫障害（狼瘡など）があります。また、主な治療法には透析・腎移植などがあります。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development
Aronora Inc
Bayer AG
BioAegis Therapeutics Inc
Daiichi Sankyo Co Ltd
Eagle Pharmaceuticals Inc
Ionis Pharmaceuticals Inc
KidneyCure Ltd
VESSL Therapeutics Ltd
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Product Development Milestones
Featured News & Press Releases
Jul 29, 2022: Ionis reports positive Phase IIb data of fesomersen for thrombosis
Jul 28, 2022: Phase 2b studies of investigational selective coagulation modulator osocimab in patients with advanced renal disease completed
Jul 19, 2021: Aronora reports positive topline data from phase 2 study of AB023 in hemodialysis patients
Dec 02, 2020: Aronora announces clinical data to be presented at the 62nd American Society of Hematology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Aronora Inc, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Bayer AG, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by BioAegis Therapeutics Inc, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Daiichi Sankyo Co Ltd, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Eagle Pharmaceuticals Inc, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by Ionis Pharmaceuticals Inc, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by KidneyCure Ltd, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Pipeline by VESSL Therapeutics Ltd, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects, 2022
End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
